Helixmith starts local trials of VM202 for treating rare disorder
Lee Han-soo Published 2020.09.22 14:54
Helixmith said that it has administered the first dose of VM202 to patients with Charcot-Marie-Tooth (CMT) disease, as part of its local phase 1 and 2a clinical trial.
Helixmith has administered the first dose of VM202 to a patient with Charcot-Marie-Tooth disease. (Helixmith)
During the trial, a research team, led by Professor Choi Byung-ok at Samsung Medical Center, plans to evaluate the safety and tolerability of VM202 in 12 CMT patients.